COVAXIN COVID-19 Vaccine Phase 3 Trial Data Shows 77.8% Efficacy
In the phase 3, trials, Bharat Biotech's COVID-19 vaccine COVAXIN showed an efficacy of 77.8 pecent. The Subject Expert Committee (SEC) on Tuesday approved the pahse 3 trial data of the vaccine.
COVID-19 Vaccine COVAXIN Shows 77.8 % Efficacy in Phase 3 Trial Data:
(SocialLY brings you all the latest breaking news, fact checks and information from social media world, including Twitter (X), Instagram and Youtube. The above post contains publicly available embedded media, directly from the user's social media account and the views appearing in the social media post do not reflect the opinions of LatestLY.)